The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: ANA, ANA Screen IFA with Reflex to Titer and Pattern IFA, ANA with Reflux
Also known as: C-Reactive Protein, CReactive Protein CRP, CRP
Also known as: ACPA, Anti-CCP, Anti-citrulline Antibody, Anti-cyclic Citrullinated Peptide, Anti-Cyclic Citrullinated Peptide (CCP) Antibody IgG, CCP, CCP Antibody, Citrullinated Peptide (CCP) IgG, Cyclic Citrullinated Peptide Antibody, Cyclic Citrullinated Peptide CCP Antibody IgG
Also known as: RF
Also known as: ESR, SED RATE, Sed Rate by Modified Westergren ESR
Also known as: Serum Urate, UA
The Rheumatoid Arthritis - Basic Plus panel contains 6 tests with 6 biomarkers.
Brief Description: The Rheumatoid Arthritis - Basic Plus Panel is an expanded diagnostic tool designed to provide a more comprehensive assessment of rheumatoid arthritis (RA) and related conditions. By evaluating key biomarkers associated with inflammation, autoimmunity, and joint health, this panel aids in the diagnosis and monitoring of RA. It is instrumental for clinicians in identifying RA at an early stage, assessing the disease's activity level, and formulating a tailored treatment approach.
Collection Method: Blood Draw
Specimen Type: Whole Blood and Serum
Test Preparation: No preparation required
Important: This panel contains ANA Screen IFA with Reflex to Titer and Pattern #249 which is a Reflex test. If ANA Screen, IFA is positive, then ANA Titer and Pattern will be performed at an additional charge of $24.95
This panel is typically ordered when symptoms suggestive of RA are present, such as joint pain, stiffness, swelling, and reduced range of motion, especially if these symptoms are more pronounced in the morning. It may also be recommended for individuals with a family history of RA or when initial testing indicates potential RA or related autoimmune conditions. The panel's broad scope helps differentiate RA from other forms of arthritis and autoimmune diseases.
The Basic Plus panel examines several crucial biomarkers:
ANA Screen, IFA with Reflex to Titer and Pattern: Identifies antinuclear antibodies, indicative of a systemic autoimmune reaction, which can occur in various autoimmune diseases, including RA.
C-Reactive Protein (CRP): A marker of inflammation that can indicate active disease states in RA and other inflammatory conditions.
Cyclic Citrullinated Peptide (CCP) IgG Antibody: Highly specific to RA, the presence of anti-CCP antibodies is a strong predictor of the disease and can signify more aggressive disease progression.
Rheumatoid Factor: An antibody found in many RA patients, its presence supports the diagnosis of RA, although it can also be seen in other conditions.
Sed Rate: Also known as erythrocyte sedimentation rate (ESR), this test measures the rate at which red blood cells sediment in a period of one hour, indicating the presence of inflammation.
Uric Acid: Elevated levels can be associated with gout, a condition that can coexist with RA or mimic some of its symptoms, making it important for differential diagnosis.
For individuals requiring an even more detailed assessment:
The Rheumatoid Arthritis - Advanced Panel builds upon the Basic Plus by incorporating a Complete Blood Count with Differential and Platelets and a Comprehensive Metabolic Panel. These additions offer insights into overall health, organ function, and potential medication side effects, crucial for managing RA comprehensively.
The Rheumatoid Arthritis - Comprehensive Panel further extends the evaluation to include Rheumatoid Factor IgA and IgG, providing a nuanced view of the rheumatoid factor's profile. This panel represents the most thorough assessment, supporting clinicians in the intricate management of RA and associated conditions.
The Basic Plus Panel facilitates the detection and differentiation of:
Rheumatoid Arthritis: By identifying specific autoantibodies and markers of inflammation, aiding in early diagnosis and treatment planning.
Autoimmune Disorders: The presence of ANA and elevated CRP levels can indicate systemic autoimmune activity beyond RA.
Healthcare professionals utilize this panel's results to confirm RA diagnosis, assess disease activity, and inform treatment decisions. Management strategies may include disease-modifying antirheumatic drugs (DMARDs), biologic agents, and lifestyle adjustments, with regular monitoring to gauge treatment efficacy and adjust as necessary.
The Rheumatoid Arthritis - Basic Plus Panel offers a critical step forward in the accurate diagnosis and effective management of rheumatoid arthritis. By providing a broader spectrum of diagnostic tests, this panel enables healthcare providers to gain deeper insights into a patient's condition, facilitating early intervention, personalized treatment plans, and improved patient outcomes in the management of RA and related autoimmune conditions.
We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.